Plasma levels of Human Granulocytic Elastase-alpha-Proteinase Inhibitor Complex (E-alpha1PI) in Leukemia by Hiller, E. & Jochum, Marianne
Volume 48 1984 Blut 
Journal of Experimental and Clinical Hematology 
Organ of Deutsche Gesellschaft für Hämatologie und Onkologie 
of Deutsche Gesellschaft für Bluttransfusion und Immunhämatologie 
and of Österreichische Gesellschaft für Hämatologie und Onkologie 
Managing Editors 
H. Heimpel, Ulm C. Mueller-Eckhardt, Gießen 
D. Huhn, Berlin G. Ruhenstroth-Bauer, München 
Advisory Board 
E. Deutsch, Wien 
L J . Dooren, Leiden 
Th. M. Fliedner, Ulm 
J. A. Forrester, London 
R. Gross, Köln 
R. Haas, München 
K. Lennert, Kiel 
S. M. Lewis, London 
H. Löffler, Kiel 
G. Lucarelli, Pesaro 
H. A. Messner, Toronto 
G. Müller-Berghaus, Gießen 
Y. H. L. Najean, Paris 
J. Neuwirt, Prag 
G. Riethmüller, München 
H. Schmid-Schönbein, Aachen 
H.G. Schwick, Marburg/L. 
H. J. Senn, St. Gallen 
W. Spielmann, Frankfurt/M. 
A. Stacher, Wien 
R. Storb, Seattle, WA 
R. L. Verwilghen, Leuven 
P. C. Vincent, Sydney 
H. D. Waller, Tübingen 
H. Wigzell, Stockholm 





The journal "Blut" was founded in 1955 by G. Blumenthal t» W. Laves f> and H. Nachtsheim t , 
and was continued by W. Stich. In 1965 the journal "Folia Haematologica N.FT was united with 
"Blut". 
The journal is the official organ of the Deutsche Gesellschaft für Hämatologie und Onkologie, 
the Deutsche Gesellschaft für Bluttransfusion und Immunhämatologie and the Österreichische 
Gesellschaft für Hämatologie und Onkologie. 
Up until Vol. 34, No. 2 (1977) inclusively "Blut" was published by J. F. Lehmanns Verlag, 
Munich. As of Vol. 34, No. 3 (1977) it has been published by Springer-Verlag Berlin Heidelberg 
New York. 
Submission of a manuscript implies that the work described has not been published before (ex-
cept in the form of an abstract or as part of a published lecture, review or thesis), that it is not 
under consideration for publication elsewhere, that its publication has been approved by all the 
authors and by the responsible authorities - tacitly or explicitly - in the institutes where the 
work was carried out and that, if accepted, it will not be published elsewhere in the same form, 
in either the same or another language, without the consent of the copyright holders. By submit-
ting a manuscript, the authors agree that the copyright for their article is transferred to the pu-
blisher if and when the article is accepted for publication. The copyright covers the exclusive 
rights to reproduce and distribute the article, including reprints, photographic reproductions, 
microform, electronic data base, video disks or any other reproductions of similar nature and 
translations. 
Photographic reproduction, microform, electronic data base, video disks or any other reproduc-
tion of text, figures, or tables from this journal is prohibited without permission obtained from 
the publisher. 
The use of general descriptive names, trade names, trade marks, etc., in this publication, even 
if the former are not specifically identified, is not to be interpreted as exempt from the relevant 
protective laws and regulations. 
While the advice and information in this journal is believed to be true and accurate at the date 
of going to press, neither the authors nor the editors nor the publisher can accept any legal 
responsibility for errors or omissions that may be made. The publisher makes no warranty, 
express or implied, with respect to the material contained herein. 
Special regulations for the USA 
Photocopies may be made for personal or internal use beyond that permitted by Section 107 
or 108 of the U.S. Copyright Law, provided a fee is paid. This fee is $ 0.20 per page or a mini-
mum of $ 1.00 if an article consists of less than five pages. Please pay this fee to the Copyright 
Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0006-5242, 
volume, and first and last page numbers of each article copied. 
The copyright owner's consent does not extend to copying for general distribution, for promo-
tion, for creating new works, or for resale. Specific written permission must be obtained from 
the publisher for such copying. 
Other regulations 
Authors of this journal can benefit from library and photocopy fees collected by VG WORT 
if certain conditions are met. If an author lives in the Federal Republic of Germany or in West 
Berlin it is recommended that he contacts Verwertungsgesellschaft WORT, Abteilung Wissen-
schaft, Goethestraße 49, D-8000 München 2, for detailed information. 
Springer-Verlag Berlin Heidelberg New York Tokyo 
Printed in Germany by Gebr. Parcus KG, Buchdruckerei und Verlagsanstalt, München, FRG 
© Springer-Verlag, Berlin Heidelberg 1984 
Contents Volume 48 
Abb, H., see Abb, J., et al 285 
Abb, J., Abb, H., Deinhardt, F.: Age-Related Decline of Human Interferon Alpha and Inter-
feron Gamma Production 285 
Anger, B., see Hoelzer, D., et al 233 
Barandun, S., see Imbach, P., et al 415 
Barandun, S., see Jungi, T.W., et al 345 
Barr, R.D., Rotter, D., Koekebakker, M.: Human Granulopoiesis in vitro: An Advantage 
in the Use of Iscove's Modified Dulbecco's Medium 45 
Bauer, J., see Küenzlen, E., et al 363 
Baumgartner, Ch., see Imbach, P., et al 415 
Becher, R., Ohl, S., Schaefer, U.W., Wendehorst, E., Quiskamp, F., Mahmoud, H.K., Schüning, 
F., Schmidt, C G . : Clonal Evolution with Isodicentric Ph1 Chromosome in Ph1 Positive 
CML: Karyotypic Conversion after Bone Marrow Transplantation . 247 
Becker, T., see Küenzlen, E., et al 363 
Benestad, H.B., Hersleth, LB.: Production of Proliferation Inhibitors by Mature Granulocytes 201 
Berdel, W.E., Theiss, W., Fink, U., Rastetter, J.: Peripheral Arterial Occlusion and Amaurosis 
fugax as the First Manifestation of Polycythemia vera. A Case Report 177 
Bertram, U., see Küenzlen, E., et al 363 
Blankenburg, G., see Witte, T. de, et al 139 
Blom, N.R., see Smit, J.W., et al 109 
Blume, K.G., see Spruce, W.E., et al 75 . 
Bock, R. De, see Jehn, U., et al 255 
Bodemann, H.H., Rieger, A., Bross, K.J., Schröter-Urban, H., Lohr, G.W.: Erythrocyte and 
Plasma Ferritin in Normal Subjects, Blood Donors and Iron Deficiency Anemia Patients 131 
Bogman, M.J., see Lenders, J.W.M., et al 171 
Boileau, J., see Gyger, M., et al 117 
Bonny, Y., see Gyger, M., et al 117 
Bredan, A.S., Bshiwah, S.M., Kumar, N.S.: The Negative Correlation between Mean Corpuscu-
lar Volume and Erythrocyte Count in Anemic and Non-Anemic Children 327 
Bröschen-Zywietz, C , see Schmidt, R.E., et al 19 
Bross, K.J., see Bodemann, H.H., et al 131 
Bshiwah, S.M., see Bredan, A.S., et al 327 
Budde, U., see Schmidt, R.E., et al 19 
Campos, L., Vu Van, H., Ville, D., Imbert, C , Gentilhomme, O., Luo, Y.C., Fiere, D., Viala, 
J.J.: Serum Beta 2 Microglobulin in Adult Myeloid Acute Leukemias 221 
Carnot, J., see Gyger, M., et al 117 
Clemetson, K.J., see Santoso, S., et al 161 
Dallegri, F., Patrone, F., Maggj, A.M., Frumento, G., Sacchetti, C : Target Cell Lysis Mediated 
by Concanavalin A-Triggered Human Neutrophils 147 
Dalmi, L., see Pecze, K., et al 291 
Deinhardt, F., see Abb, J., et al 285 
Deveridge, S.F., see Young, G.A.R., et al 153 
Diederichsen, H., see Schmidt, K.G., et al 27 
Dopfer, R., see Gaedicke, G., et al 387 
Emmerich, B., see Maubach, P.A., et al 243 
Eridani, S., see Fiorini, G., et al 321 
Fahey, J.L., see Spruce, W.E., et al 75 
Falcäo, R.P., see Ideriha, N.M., et al 277 
Farbstein, M.J., see Spruce, W.E., et al 75 
Fauser, A.A., see Neumann, H.A., et al 227 
Fiere, D., see Campos, L., et al 221 
IV Contents 
Fink, U., see Berdel, W.E., et al 177 
Fiorini, G., Geniram, A., Frezzini, G., Eridani, S.: Patterns of T Cell Subset Alterations in 
Myelo- and Lymphoproliferative Disorders 321 
Fischer, P., see Haas, OA., et al , 33 
Flury, R., see Schmid, L., et al 11 
Forman, S.J., see Spruce, W.E., et al 75 
Forrest, P.R., see Morris, T.C.M., et al 61 
Forrest, P.R., see Young, G.A.R., et al 153 
Förster, C , see Mueller-Eckhardt, C , et al 353 
Frezzini, G., see Fiorini, G., et al 321 
Frumento, G., see Dallegri, F., et al 147 
Gaedicke, G., Imbach, P., Kleihauer, E.: The Place of Intravenous Immunoglobulin (IgG 
i.v.) Therapy in Thrombocytopenia 409 
Gaedicke, G., Teller, W.M., Kohne, E., Dopfer, R., Niethammer, D.: IgG Therapy in Systemic 
Lupus Erythematosus. Two Case Reports 387 
Gaedicke, G., see Imbach, P., et al 357 
Gaedicke, G., see Imbach, P., et al 415 
Gaedicke, G., see Imbach, P 335 
Gaedicke, G., see Seifried, E., et al 397 
Gaedicke, G., see Wenske, G., et al 377 
Gallango, M.L., Suinaga, R., Ramirez, M.: An Unusual Case of Waldenstrom Macroglobuline-
mia with Half Molecules of IgG in Serum and Urine 91 
Ganser, A., see Hoelzer, D., et al 233 
Gardi, A.: Quality Control in the Production of an Immunoglobulin for Intravenous Use . . 337 
Gascon, P., see Zoumbos, N., et al 1 
Gassmann, W., see Schmitz, N., et al 263 
Geestman, E., see Witte, T. de, et al 139 
Geniram, A., see Fiorini, G., et al 321 
Gentilhomme, O., see Campos, L., et al 221 
Gianella-Borradori, A., Hirt, A., Lüthy, A., Wagner, H.P., Imbach, P.: Haemophilia Due 
to Factor VIII Inhibitors in a Patient Suffering from an Autoimmune Disease: Treatment 
with Intravenous Immunoglobulin. A Case Report 403 
Gödde-Salz, E., see Schmitz, N., et al 263 
Goebel, F.D., see Hehlmann, R., et al 297 
Graubner, M., see Salama, A., et al 391 
Gunzer, U., see Rüter, A 307 
Gyger, M., Perreault, C , Carnot, J., Boileau, J., Bonny, Y.: Treatment of Therapy-Induced 
Preleukemic Syndrome 117 
Haanen, C , see Jehn, U., et al 255 
Haanen, C , see Lenders, J.W.M., et al 171 
Haanen, C , see Witte, T. de, et al 139 
Haas, O.A., Schwarzmeier, J.D., Nacheva, E., Fischer, P., Paietta, E.: Investigations on Karyo-
type Evolution in Patients with Chronic Myeloid Leukemia (CML) 33 
Halie, M.R., see Smit, J.W., et al 109 
Haschke, F., see Zeitlhuber, U., et al 393 
Hehlmann, R., Luderschmidt, C , Goebel, F.D., Henze, K.: Relapsing Acute Febrile Neutro-
philic Dermatosis and Essential Thrombocythemia 297 
Heimpel, H., see Hoelzer, D., et al 233 
Heimpel, H., see Seifried, E., et al 369 
Heit, W., see Schmid, L., et al 11 
Henke, M., see Spruce, W.E., et aL 75 
Henze, K., see Hehlmann, R., et al 297 
Hersleth, I.B., see Benestad, H.B 201 
Heyes, H., see Wenske, G., et al 377 
Hiller, E., Jochum, M.: Plasma Levels of Human Granulocytic Elastase a rProteinase Inhibitor 
Complex (E-a,-Pl) in Leukemia 269 
Hirt, A., see Gianella-Borradori, A., et al 403 
Contents V 
Hirt, A., see Imbach, P., et al 415 
Hoelzer, D., Ganser, A., Anger, B., Seifried, E., Heimpel, H.: Low-dose Ara-C in the Treatment 
of Acute Leukemia Cytotoxicity or Differentiation Induction? 233 
Horst, J., Oehme, R., Kleihauer, E., Kohne, E.: Hemoglobin Köln: Analysis of Linkage Rela-
tionships between the Mutant Gene and Polymorphic Restriction Sites in the /?-Globin Gene 
Cluster 213 
Hossfeld, D.K., see Weh, HJ. , et al 239 
Hunstein, W., see Körbling, M 189 
Ideriha, N.M., Vugman, I., Falcäo, R.P.: Ectopic Bone Marrow Development in Experimental 
Busulfan-Induced Hypoplastic Anemia in Mice 277 
Hand, H.J., see Young, G.A.R., et al 153 
Imbach, P., Barandun, S., Baumgartner, Ch., Gaedicke, G., Hirt, A., Wagner, H.P.: Intravenous 
Immunoglobulin Therapy: New Aspects and Outlook 415 
Imbach, P., Gaedicke, G.: Editorial 335 
Imbach, P., Gaedicke, G., Joller, P.: Interim Evaluation of two Cooperative Studies Assessing 
the Effects of Intravenous Immunoglobulin (i.v. IgG) on Childhood Idiopathic Thrombocyto-
penic Purpura (ITP): I. Randomized Study Comparing i.v. IgG with Oral Corticosteroids 
in Previously Untreated Acute ITP. II. Prospective Study of i.v. IgG in Acute and Chronic 
ITP Unresponsive to Previous Treatment 357 
Imbach, P., see Gaedicke, G., et al 409 
Imbach, P., see Gianella-Borradori, A., et al 403 
Imbach, P., see Jungi, T.W., et al 345 
Imbach, P., see Zeitlhuber, U., et al 393 
Imbert, C , see Campos, L., et al 221 
Imhoff, G.W. van, see Smit, J.W., et al 109 
Isbister, J.P., see Morris, T.C.M., et al 61 
Jehn, U., Bock, R. De, Haanen, C : Clinical Trial of Low-Dose Ara-C in the Treatment 
of Acute Leukemia and Myelodysplasia 255 
Joch um, M., see Hiller, E 269 
Joller, P., see Imbach, P., et al 357 
Jungi, T.W., Imbach, P., Barandun, S.: Specific and Nonspecific Mechanisms of Action of 
Immunoglobulin G in Therapy of Idiopathic Thrombocytopenic Purpura (ITP) 345 
Kiefel, V., see Mueller-Eckhardt, C , et al 353 
Kiss, A., see Pecze, K., et al 291 
Kleihauer, E., see Gaedicke, G., et al 409 
Kleihauer, E., see Horst, J., et al 213 
Knapp, W., see Zeitlhuber, U., et al 393 
Koekebakker, M., see Barr, R.D., et al 45 
Koekman, E., see Witte, T. de, et al 139 
Kohne, E., see Gaedicke, G., et al 387 
Kohne, E., see Horst, J., et al 213 
Körbling, M., Hunstein, W.: In Vitro Chemoseparation as Part of Autologous Bone Marrow 
Transplantation (ABMT) in Hematologic Malignancy 189 
Krance, R.A., see Spruce, W.E., et al 75 
Küenzlen, E., Bauer, J., Bertram, U., Becker, T., Lampert, F., Röttger, P., Mueller-Eckhardt, 
C.: Fatal Outcome of Acute Thrombocytopenic Purpura Associated with a Viral Infection 
in an 11-Year-Old Child 363 
Küenzlen, E., see Mueller-Eckhardt, C , et al 353 
Kumar, N.S., see Bredan, A.S., et a l 327 
Kurz, H., Leder, O.: The Compactness of Populations of Neutrophilic Leucocytes as Revealed 
by the New Azure B-Eosine Stain, Pappenheim's Stain and the Peroxidase Reaction . . . 49 
Laier, G., see Lakomek, M., et al 123 
Lakomek, M., Winkler, H., Scharnetzky, M., Tillmann, W., Laier, G., Marti, H.R., Schröter, 
W.: Erythrocyte Pyruvate Kinase Deficiency: Characterization of a New Variant (PK 
"Aarau") 123 
Lampert, F., see Küenzlen, E., et al 363 
Lechner, K., see Zeitlhuber, U., et al 393 
VI Contents 
Leder, O., see Kurz, H 49 
Lenders, J.W.M., Pauw, B.E. de, Bogman, M.J., Haanen, C : Combined Immunodeficiency 
Preceding Chronic Lymphocytic Leukemia 171 
Lennert, K., see Zankowich, R., et al 99 
Loftier, H., see Schmitz, N., et al 263 
Lohmeyer, J., see Santoso, S., et al 161 
Lohr, G.W., see Bodemann, H.H., et al 131 
Lohr, G.W., see Neumann, H.A., et al 227 
Luderschmidt, C , see Hehlmann, R., et al 297 
Luo, Y.C., see Campos, L., et al 221 
Lüthy, A., see Gianella-Borradori, A., et al 403 
Luyn, MJ.A. van, see Smit, J.W., et al 109 
Maggi, A.M., see Dallegri, F., et al 147 
Mahmoud, H.K., see Becher, R., et al 247 
Mahn, I., see Salama, A., et al 391 
Marti, H.R., see Lakomek, M., et al. 123 
Maubach, P.A., Emmerich, B., Willer, A., Ogilvie, A., Rastetter, J.: Urinary Glycoproteins 
in Acute Leukemias: a 41000dalton Glycoprotein Follows the Kinetic of Cytoreduction 243 
Morgenstern, E., Reimers, HJ . : The Platelet Contacts during Aggregation 81 
Morris, T.C.M., Vincent, P.C., Young, G.A.R., Sutherland, R., Forrest, P.R., Isbister, J.P.: 
CFU-C Inhibitors in Aplastic Anaemia 61 
Mueller-Eckhardt, C , Salama, A., Kiefel, V., Küenzlen, E., Förster, C : A New Concept 
for the Effector Mechanism of Intravenous Immunoglobulin in Hemocytopenias 353 
Mueller-Eckhardt, C , see Küenzlen, E., et al 363 
Mueller-Eckhardt, C , see Salama, A., et al 391 
Mueller-Eckhardt, C , see Santoso, S., et al 161 
Mueller-Eckhardt, C , see Schmidt, R.E., et al 19 
Nacheva, E., see Haas, O.A., et al 33 
Nademanee, A.P., see Spruce, W.E., et al 75 
Neumann, H.A., Lohr, G.W., Fauser, A.A.: Tumor Cell Colonies in Bone Marrow Cultures 
from Patients with Small Cell Carcinoma of the Lung 227 
Neuzner, J., see Salama, A., et al 391 
Niethammer, D., see Gaedicke, G., et al 387 
Oehme, R., see Horst, J., et al 213 
Ogilvie, A., see Maubach, P.A., et al. 243 
Ohl, S., see Becher, R., et al 247 
Paietta, E., see Haas, O.A., et al 33 
Parwaresch, M.R., see Zankowich, R., et al 99 
Patrone, F., see Dallegri, F., et al 147 
Pauw, B.E. de, see Lenders, J.W.M., et al 171 
Pecze, K., Pfliegler, G., Dalmi, L., Kiss, A., Rak, K.: Detection of Platelet-Associated IgG 
in Chronic Immune Thrombocytopenic Purpura Using Antibody-Coated Polyacrylamide 
Beads 291 
Perreault, C , see Gyger, M., et al 117 
Pfliegler, G., see Pecze, K., et al 291 
Pindur, G., see Seifried, E., et al 369 
Pindur, G., see Seifried, E., et al 397 
Pias, A., see Witte, T. de, et al 139 
Püspök, R., see Zeitlhuber, U., et al 393 
Quiskamp, F., see Becher, R., et al 247 
Rak, K., see Pecze, K., et al 291 
Ramirez, M., see Gallango, M.L., et al 91 
Rasche, H., see Seifried, E., et al 369 
Rasche, H., see Seifried, E., et al 397 
Rasmussen, J.W., see Schmidt, K.G., et al 27 
Rastetter, J., see Berdel, W.E., et al 177 
Rastetter, J., see Maubach, P.A., et al 243 
Contents VII 
Reimers, HJ . , see Morgenstern, E 81 
Rennich, H., see Santoso, S., et al 161 
Rieger, A., see Bodemann, H.H., et al 131 
Rotter, D., see Barr, R.D., et al 45 
Röttger, P., see Küenzlen, E., et al 363 
Rüter, A., Gunzer, U.: Differentiation of Granulocytes in Pappenheim Stained Blood Cell 
Smears Using Standardized Cytophotometric Analysis 307 
Sacchetti, C , see Dallegri, F., et al 147 
Salama, A., Mahn, I., Neuzner, J., Graubner, M., Mueller-Eckhardt, C : IgG Therapy in 
Autoimmune Haemolytic Anaemia of Warm Type 391 
Salama, A., see Mueller-Eckhardt, C , et al 353 
Santoso, S., Lohmeyer, J., Rennich, H., Clemetson, K.J., Mueller-Eckhardt, C.: Platelet Surface 
Antigens: Analysis by Monoclonal Antibodies. I. Immunological and Biochemical Studies 161 
Schaefer, U.W., see Becher, R., et al 247 
Schäfer, G., see Schmidt, R.E., et al 19 
Scharnetzky, M., see Lakomek, M., et al 123 
Schmeiser, Th.: Autologous Bone Marrow Transplantation (ABMT) in Solid Tumors. ABMT 
Workshop - Organized by the E.O.R.T.C. Lung Cancer Cooperative Group (Chairman: 
Dr. J.G. McVie), Amsterdam, June 11, 1983 53 
Schmid, L., Heit, W., Flury, R.: Agranulocytosis Associated with Semisynthetic Penicillins 
and Cephalosporins Report of 7 Cases 11 
Schmidt, C.G., see Becher, R., et al 247 
Schmidt, K.G., Rasmussen, J.W., Diederichsen, H., Ulrich, M.: Release of Platelets into the 
Circulation Induced by Gamma Globulin Treatment in a Case of Idiopathic Thrombocyto-
penic Purpura 27 
Schmidt, R.E., Budde, U., Bröschen-Zywietz, C , Schäfer, G., Mueller-Eckhardt, C : High 
Dose Gammaglobulin Therapy in Adults with Idiopathic Thrombocytopenic Purpura (ITP) 
Clinical Effects 19 
Schmitz, N., Gödde-Salz, E., Gassmann, W., LöfTler, H.: Acute Myelomonocytic Leukemia 
with Involvement of Eosinophils and Inversion of Chromosome 16 263 
Schröter, W., see Lakomek, M., et al 123 
Schröter-Urban, H., see Bodemann, H.H., et al 131 
Schüning, F., see Becher, R., et al 247 
Schwarzmeier, J.D., see Haas, O.A., et al 33 
Scott, E.P., see Spruce, W.E., et al 75 
Seifried, E., Gaedicke, G., Pindur, G., Rasche, H.: The Treatment of Haemophilia A Inhibitor 
with High Dose Intravenous Immunoglobulin 397 
Seifried, E., Pindur, G., Stötter, H., Wiesneth, M., Rasche, H., Heimpel, H.: Treatment of 
Refractory Chronic Idiopathic Thrombocytopenic Purpura with High Dose Intravenous Im-
munoglobulin 369 
Seifried, E., see Hoelzer, D., et al 233 
Sidiropoulos, D., Straume, B.: The Treatment of Neonatal Isoimmune Thrombocytopenia 
with Intravenous Immunoglobulin (IgG i.v.) 383 
Smit, J.W., Blom, N.R., Luyn, M.J.A. van, Imhoff, G.W. van, Halie, M.R.: Effect of Sera 
from Patients with Hodgkin's Disease on Normal Donor Lymphocytes Containing Parallel 
Tubular Structures 109 
Spruce, W.E., Forman, S J. , Krance, R.A., Farbstein, M J., Wolf, J.L., Scott, E.P., Nademanee, 
A.P., Fahey, J.L., Henke, M., Blume, K.G.: Outcome of Bone Marrow Transplantation 
in Patients with Extramedullar Involvement of Acute Leukemia 75 
Stötter, H., see Seifried, E., et al 369 
Straume, B., see Sidiropoulos, D 383 
Suinaga, R., see Gallango, M.L., et al 91 
Sutherland, R., see Morris, T.C.M., et al 61 
Teller, W.M., see Gaedicke, G., et al 387 
Theiss, W., see Berdel, W.E., et al 177 
Tillmann, W., see Lakomek, M., et al 123 
Ulrich, M., see Schmidt, K.G., et al 27 
VIII Contents 
Viala, J.J., see Campos, L., et al 221 
Ville, D., see Campos, L., et al 221 
Vincent, P.C., see Morris, T.C.M., et al 61 
Vincent, P.C., see Young, G.A.R., et al 153 
Vu Van, H., see Campos, L., et al 221 
Vugman, I., see Ideriha, N.M., et al 277 
Wagner, H.P., see Gianella-Borradori, A., et al 403 
Wagner, H.P., see Imbach, P., et al 415 
Waller, H.D.: Professor Dr. Dr. h.c. Hans Erhard Bock 80 Jahre alt 187 
Weh, HJ. , Zschaber, R., Hossfeld, D.K.: Low-dose Cytosine-Arabinoside in the Treatment 
of Acute Myeloid Leukemia (AML) and Myelodysplasie Syndrome (MDS) 239 
Wendehorst, E., see Becher, R., et al 247 
Wenske, G., Gaedicke, G., Heyes, H.: Idiopathic Thrombocytopenic Purpura in Pregnancy 
and Neonatal Period 377 
Wessels, J., see Witte, T. de, et al 139 
Wiesneth, M., see Seifried, E., et al 369 
Willer, A., see Maubach, P.A., et al 243 
Winkler, H., see Lakomek, M., et al 123 
Witte, T. de, Koekman, E., Geestman, E., Pias, A., Blankenburg, G., Wessels, J., Haanen, 
C.: Separation of Immunoreactive Lymphocytes from Human Pluripotent Stem Cells (CFU-
GEMM) by Means of Counterflow Centrifugation 139 
Wolf, J.L., see Spruce, W.E., et al 75 
Young, G.A.R., Hand, HJ. , Deveridge, S.F., Forrest, P.R., Vincent, P.C.: Steroid Responsive 
Cyclical Neutropenia 153 
Young, G.A.R., see Morris, T.C.M., et al 61 
Young, N., see Zoumbos, N., et al 1 
Zankowich, R., Parwaresch, M.R., Lennert, K.: Blood Findings in Lymphogranulomatosis X 99 
Zeitlhuber, U., Haschke, F., Püspök, R., Lechner, K., Knapp, W., Imbach, P.: Hemophilia 
and Thrombocytopenia in a Patient with Impaired Cellular Immunity. A Case Report . . 393 
Zoumbos, N., Gascon, P., Young, N.: The Function of Lymphocytes in Normal and Suppressed 
Hematopoiesis 1 
Zschaber, R., see Weh, HJ . , et al 239 
Subject Index 419 
Author Index 423 
Book Reviews 425 
Indexed in Current Contents 
Blut (1984) 48: 269-275 Blut 
© Springer-Verlag 1984 
Plasma Levels of Human Granulocytic Elastase 
ai-Proteinase Inhibitor Complex (E-«i-PI) in Leukemia 
E. Hiller1 and M. Jochum2 
1 Medizinische Klinik III im Klinikum Großhadern der Universität München, 
D-8000 München 70, Federal Republic of Germany 
2 Abteilung für Klinische Chemie und Klinische Biochemie in der Chirurgischen Klinik 
Innenstadt der Universität München, D-8000 München, Federal Republic of Germany 
Summary. There is evidence that polymorphonuclear granulocytes release neutral 
proteinases such as elastase (E) and cathepsin G in the course of acute leukemia. 
These proteinases may inactivate clotting factors by unspecific degradation before 
they are eliminated via complex formation with endogenous inhibitors, e. g. the 
arproteinase inhibitor (arPI). In this study it was attemped to correlate plasma 
levels of the E-arPI complex with factor XIII and antithrombin III in acute 
leukemia. Using a newly developed, sensitive enzyme-linked immunoassay the 
concentration of E-arPI in patients with various types of leukemia, malignant 
lymphoma or multiple myeloma was determined. Only patients with acute myelo-
cytic or promyelocytic leukemia (AML, APL) and chronic myelocytic leukemia 
with and without blastic transformation (CML) showed moderate to high levels of 
E-arPI (2- to 20-fold of normal). However, coagulation factor concentration 
observed in the different types of leukemia seemed to be independent of elastase 
liberation. Most of the AML-patients with elevated E-arPI levels showed peroxid-
ase positive blood cell smears. 
Key words: Elastase - a,-proteinase-inhibitor - Factor XIII - AT III - Leu-
kemia 
Bleeding in acute leukemia is common and frequently caused by thrombocytopenia. 
However, consumption of plasmatic coagulation factors may also contribute to bleed-
ing in leukemic patients. Generally it is thought that the release of procoagulant 
material (tissue factor) from leukemic cells specifically triggers the coagulation and 
fibrinolysis systems thus leading to disseminated intravascular coagulation (DIC) 
[4,8,17]. Possibly, even small amounts of monocytes account for most of the tissue 
factor activity [16]. 
Recent investigations indicate that lysosomal proteinases released from white cells 
may also contribute to the consumption of coagulation factors [1,2, 3,7]. Especially 
neutrophil elastase may destroy plasma proteins before inhibition occurs by arprotein-
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Fig. 1. Principle of the enzyme-linked immunoassay used for determination of the elastase-
ofj-proteinase inhibitor complex (E-ttjPI). ab-E = antibodies against human granulocytic 
elastase; ab a,PI(-AP) = antibodies against human a rproteinase inhibitor, labelled with 
alkaline phosphatase 
ase inhibitor (or,-PI) and a2-macroglobulin (a2M). Because these inhibitors are present 
in excess direct measurement of the granulocytic proteinase activities in plasma is not 
possible. However, increased levels of the elastase Of r PI complex (E-ajPI) would be 
an indirect but clear indication of elastase liberation. Such complexes have been de-
monstrated occasionally by others applying one- and two-dimensional Laurell electro-
phoresis to plasma samples of patients with septicemia or acute leukemia [3]. 
In our study quantitative estimation of the E-c^PI plasma levels in patients with 
leukemia was performed with a highly sensitive enzymelinked immunoassay which 
has been developed recently by Neumann et al. [14]. To see whether a relationship 
exists between the concentration of E-ofjPI and the consumption of plasma proteins, 
we determined the levels of factor XIII (F XIII) and antithrombin III (AT III), 
because both clotting factors are known to be very sensitive substrates for granulo-
cytic elastase in vitro [2,6]. 
Materials and Methods 
Blood samples were obtained from 32 patients with acute leukemia (26 with AML, 6 with ALL), 
8 patients with chronic myelocytic leukemia (CML), 3 patients with chronic lymphocytic 
leukemia (CLL), 6 patients with multiple myeloma and 4 patients with centrocytic-centroblastic 
lymphoma. Nine parts of blood were mixed with one part of 0.13 mol/1 Na-citrate. Platelet-poor 
plasma was prepared in a refrigerated centrifuge (3000 g, 20 min, 4°C). The plasma samples 
were stored at -40° until assayed. 
The enzyme-linked immunoassay for E-ajPI was performed according to Neumann et al. [14]. 
The principle of the assay is outlined in Fig. 1. Briefly, plasma samples were incubated in plastic 
tubes coated with antibodies against elastase. After washing with buffer, the surface-fixed 
E-or,PI complex molecules reacted with alkaline phosphatase (AP)-labelled antibodies directed 
against c^PI. Under the conditions used the activity of A P towards p-nitrophenylphosphate is 
proportional to the concentration of E-a tPI in the sample. 
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Fig. 2. Elastase-a,-proteinase inhibitor complex (E-a,PI) levels in plasma of patients with 
various types of leukemia, multiple myeloma or malignant lymphoma on admission. AML = 
acute myelocytic leukemia; APL = acute promyelocyte leukemia; CML = chronic myelocytic 
leukemia with blastic transformation; ALL = acute lymphatic leukemia; CLL = chronic 
lymphatic leukemia 
Antithrombin III (AT III) was determined photometrically using the chromogenic thrombin 
substrate S-2238 (Deutsche Kabi, Munich) [15] and in some samples fluorimetrically (Proto-
path, Dade, Munich) [13]. The functional activity of the fibrin stabilizing factor (F XIII) was 
measured with a commercial test kit (Faktor Xlll-Schnelltest, Behringwerke, Marburg) as 
described by Karges [10]. Plasma levels of F XIII subunit A and S were assayed with the Laurell 
electrophoresis [11] using monospecific antisera directed against either subunit A or S (Behring-
werke, Marburg). The peroxidase staining was performed according to Kaplow [9]. 
With the enzyme-linked immunoassay normal levels of complexed elastase were found 
between 40 and 150 ng/ml in 153 healthy individuals (mean value 86.5 ±25.5 ng/ml). 
Plasma levels of the E-c^PI complex were determined in 53 untreated patients with 
different types of leukemia, malignant lymphoma and multiple myeloma. Elevated 
levels were found only in patients with acute myelocytic and promyelocytic leukemia 
(AML, APL) as well as chronic myelocytic leukemia (CML) in the chronic phase and 
blastic transformation (Fig. 2). The highest amounts of E-aJ3! were observed in CML 
patients: in 5 of the 8 subjects more than 1000 ng/ml (i. e. 10 times the normal value) 
of complexed elastase were found. In acute and chronic lymphatic leukemia (ALL, 
Results 
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CLL), malignant lymphoma and multiple myeloma E-a^l plasma levels were normal 
or only slightly elevated (Fig. 2). 
In 27 patients with the diagnosis of acute leukemia the peroxidase reaction was 
also performed. In 18 patients it was positive and 15 out of the 18 patients (83%) had 
elevated levels of E-c^PI. In all 18 patients the diagnosis was acute myelocytic leuke-
mia. Of the 9 patients with peroxidase negative smears only 1 (11%) had an increased 
concentration of granulocytic elastase. This patient had morphologically an acute 
myelomonocytic leukemia. The same diagnosis was true for a second patient whose 
E-ajPI levels, however, were not elevated. In an additional patient with the morpho-
logical features of acute myelocytic leukemia a partial myeloperoxidase deficiency was 
present. The remaining 6 patients had acute lymphocytic leukemia. 
In Table 1, the levels of E-ajPI, F XIII and ATIII as well as the corresponding leuko-
cyte counts are summarized for 24 patients with AML, APL, CML and ALL. In the 
remaining 14 patients whose E-GfjPI levels are depicted on Fig. 2 the coagulation data 
are incomplete and therefore not recorded. Obviously, there is only a poor correlation 
between the individual numbers of leukocytes and the complexed elastase as well as 
each of the clotting factors. The fibrin stabilizing activity of F XIII was reduced to 
62.5% or less of the norm in more than half of the AML and APL patients. However, 
this reduction was independent of the amount of E-a^Pl present in the same samples. 
The extremely low F XIII activity in patients with ALL was expecially striking con-
sidering their normal E-c^PI levels. Moreover, CML patients showed F XIII activities 
in the normal range although the E-ajPI complex was highly elevated. In a few cases, 
F XIII subunit A and S levels were also determined. No parallel decrease in either 
subunit characteristic for proteolytic degradation could be demonstrated. The AT III 
activity was in the normal range (75% up to 115%) in more than 70% of the patients 
studied. The reduced thrombin inhibitory capacity of the remaining subjects was 
correlated neither to the amount of complexed elastase nor to the F XIII activity. 
Figure 3 depicts the rapid decrease in complexed elastase during remission induc-
tion chemotherapy in a patient with AML. E-ofjPI was normal following hematologic 
remission. 
Discussion 
On the basis of in vitro and in vivo studies Egbring et al. [3] postulated that in addi-
tion to DIC direct proteolysis by granulocytic proteinases contributes considerably to 
the consumption of clotting factors in patients with acute leukemia or septicemia. In-
creased levels of complexed granulocytic elastase in the circulation were regarded as 
an indication of extracellular elastase release. Furthermore, the concomitant decrease 
in the fibrin stabilizing activity as well as the amount of F XIII subunit A and S were 
thought to be a consequence not only of clotting but also of proteolytic degradation 
by liberated elastase. Applying the Laurell technique for the determination of the 
E-ci^ PI complex in plasma, the authors divided their leukemia patients into two 
groups: those with and those without ofjPI-bound elastase. Reduction in F XIII 
activity, decrease in both subunits of F XIII and increased levels of fibrin (ogen) 
degradation product (FDP) correlated well with the presence, yet not with the absolute 
amount of complexed elastase in plasma. However, in a number of specimens without 
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Fig. 3. Leukocyte counts and plasma levels of elastase-a,-proteinase inhibitor complex (E-a,PI) 
in a 51 year old patient with acute myelocytic leukemia (AML) during remission induction 
chemotherapy (ADM = adriamycine; VCR = vincristine; ARA-C = cytosine arabinoside). 
Abscissa: time after admission. First day of treatment day 8 
ajPI-bound elastase the levels of clotting factors were also pathological. This dis-
crepancy might to some extent be due to the limited sensitivity and accuracy of the 
elastase assay applied by these authors. With the newly developed and highly sensitive 
enzyme-linked immunoassay, the lower working range for elastase in complex with 
c^PI is 0.2 ng per assay, i. e. 20 ng/ml plasma. Thus, even E-ajPI levels in plasma 
samples of healthy individuals could be accurately measured (normal range: 60 to 
110 ng/ml; Neumann et al [14]). 
In our first approach to study E-o^PI levels in leukemia, we found moderately to 
highly elevated levels in CML patients with and without blastic transformation. AML 
and APL patients showed a wide variety of E-a/PI levels ranging from normal to 
more than twenty fold higher values, independent of the individual leukocyte counts. 
Interestingly, in most of the patients with peroxidase positive leukemic cells the 
E-c^PI complex was clearly elevated, and vice versa. This might indicate various states 
of differentiation and maturation of the leukemic blood cells. 
The present study of E-ay PI levels in leukemia does not explain the significance 
of elevated amounts of complexed elastase in relation to the changes of F XIII and 
AT III in plasma. In contrast to the results of Egbring et al. [3] we could not find 
a correlation between the levels of E-ajPI and F XIII in any of the leukemia groups 
studied. Whereas in the patients with AML a wide spectrum of F XIII values was 
obtained independently of the amount of E-c^PI, the activity of F XIII in patients 
with CML was normal in spite of the high levels of E-ci^ PL There was also a striking 
discrepancy between the normal amount of E-a^l and the very low levels of F XIII 
in the 4 patients with ALL. It is well known that the treatment protocols for ALL 
patients include asparaginase which blocks hepatic protein synthesis [12]. This results 
in a decrease in coagulation factors such as fibrinogen, AT III and F XIII which are 
synthesized in the liver. The data of the 4 ALL patients, however, were obtained prior 
to the treatment with asparaginase. 
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Table 1. Leukocyte counts and plasma levels of elastase-aj -proteinase inhibitor complex (E-
a,PI), factor XIII (fibrin stabilizing activity as well as subunit A and S), and antithrombin III 
(AT III) in patients with acute myelocytic leukemia (AML), promyelocytic leukemia (APL), 
chronic myelocytic leukemia (CML, o = chronic phase, x = blastic transformation), and acute 
lymphocytic leukemia (ALL), n. d. = not done 
F XIII 
Patients Diagnosis Leukocytes E ^ P I ( x 10Vol) (ng/ml) Functional A 
o/o 
S AT III 
°7o 
Kh AML 3.5 27 87.5 87 
Re AML 4 66 62.5 98 
Ec AML 10.6 96 37.5 66 
Mi AML 17.5 125 100 56.5 112.5 63 
Schö AML 163 170 50 70 
Hi AML 4.1 640 62.5 83 
Bo AML 17.9 840 50 50 74.5 88 
Ha AML 140 1140 50 62.5 80 98 
Ri AML 59.8 1540 87.5 53.5 100.5 n. d. 
Ke AML 49.9 2045 100 87.5 120.5 n. d. 
Sehn APL 2 330 25 25 25 82 
We APL 1.6 1320 87.5 104 
Si APL 52 1600 n. d. 69 
Me CMLX 7.8 132 120 109 
Bo CMLX 174 336 75 109 
Ri CML 0 381 750 75 110 
Ay CMLX 76 1000 120 107 
Eg CML0 170 1025 87.5 76.5 136 n. d. 
Vo CMLX 15 1140 100 59 110 n. d. 
Ex CMLX 130 2120 100 45 106.5 n. d. 
Rei CML 0 247 3585 100 67 
He ALL 32 64 25 85 
Sa ALL 35 64 25 70 
Ri ALL 69.5 68 25 100 
Schi ALL 36 76 37.5 105 
Only recently was it demonstrated by serial determinations that a clear correlation 
exists between E-aiPI increase and the decrease of both F XIII subunits in plasma 
of patients dying from postoperative septicemia [15]. In partial agreement with Eg-
bring et al. [3] the conclusion was drawn that in patients with septicemia elastase or 
other lysosomal proteinases are involved to a significant degree in the depletion of F 
XIII. The data presented here, however, suggest that in acute leukemia the mechanism 
of F XIII depletion is independent of the liberation of elastase from leukocytes and, 
therefore, different from that postulated for septicemia. One reason for this dis-
crepancy might be a different release mechanism in both diseases. In septicemia, 
elastase and other lysosomal proteinases should be liberated in high amounts pre-
ferably locally due to exogenous stimuli like endotoxins, opsonized particles, immune 
complexes etc. Hence, the inhibitory potential at or close to the infection focus might 
be temporarily overstressed thus allowing uncontrolled proteolytic degradation by 
lysosomal proteinases. In leukemia, however, elastase is probably released systemically 
Human Granulocytic Elastase 275 
in amounts depending on the rate and mode of turnover of the leukocytes. In contrast 
to septicemia, the endogenous inhibitors are likely able to prevent unspecific pro-
teolytic degradation of plasma proteins more effectively during a systemic release 
reaction. The low F XIII activity in some leukemia patients could be the result of 
either abnormal low synthesis or enhanced turnover of this protein due to factors not 
yet identified. 
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